Quantitative computed tomography predicts outcomes in idiopathic pulmonary fibrosis.


Journal

Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368

Informations de publication

Date de publication:
12 2022
Historique:
received: 29 12 2021
accepted: 03 07 2022
pubmed: 26 7 2022
medline: 22 11 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

Prediction of disease course in patients with progressive pulmonary fibrosis remains challenging. The purpose of this study was to assess the prognostic value of lung fibrosis extent quantified at computed tomography (CT) using data-driven texture analysis (DTA) in a large cohort of well-characterized patients with idiopathic pulmonary fibrosis (IPF) enrolled in a national registry. This retrospective analysis included participants in the Australian IPF Registry with available CT between 2007 and 2016. CT scans were analysed using the DTA method to quantify the extent of lung fibrosis. Demographics, longitudinal pulmonary function and quantitative CT metrics were compared using descriptive statistics. Linear mixed models, and Cox analyses adjusted for age, gender, BMI, smoking history and treatment with anti-fibrotics were performed to assess the relationships between baseline DTA, pulmonary function metrics and outcomes. CT scans of 393 participants were analysed, 221 of which had available pulmonary function testing obtained within 90 days of CT. Linear mixed-effect modelling showed that baseline DTA score was significantly associated with annual rate of decline in forced vital capacity and diffusing capacity of carbon monoxide. In multivariable Cox proportional hazard models, greater extent of lung fibrosis was associated with poorer transplant-free survival (hazard ratio [HR] 1.20, p < 0.0001) and progression-free survival (HR 1.14, p < 0.0001). In a multi-centre observational registry of patients with IPF, the extent of fibrotic abnormality on baseline CT quantified using DTA is associated with outcomes independent of pulmonary function.

Sections du résumé

BACKGROUND AND OBJECTIVE
Prediction of disease course in patients with progressive pulmonary fibrosis remains challenging. The purpose of this study was to assess the prognostic value of lung fibrosis extent quantified at computed tomography (CT) using data-driven texture analysis (DTA) in a large cohort of well-characterized patients with idiopathic pulmonary fibrosis (IPF) enrolled in a national registry.
METHODS
This retrospective analysis included participants in the Australian IPF Registry with available CT between 2007 and 2016. CT scans were analysed using the DTA method to quantify the extent of lung fibrosis. Demographics, longitudinal pulmonary function and quantitative CT metrics were compared using descriptive statistics. Linear mixed models, and Cox analyses adjusted for age, gender, BMI, smoking history and treatment with anti-fibrotics were performed to assess the relationships between baseline DTA, pulmonary function metrics and outcomes.
RESULTS
CT scans of 393 participants were analysed, 221 of which had available pulmonary function testing obtained within 90 days of CT. Linear mixed-effect modelling showed that baseline DTA score was significantly associated with annual rate of decline in forced vital capacity and diffusing capacity of carbon monoxide. In multivariable Cox proportional hazard models, greater extent of lung fibrosis was associated with poorer transplant-free survival (hazard ratio [HR] 1.20, p < 0.0001) and progression-free survival (HR 1.14, p < 0.0001).
CONCLUSION
In a multi-centre observational registry of patients with IPF, the extent of fibrotic abnormality on baseline CT quantified using DTA is associated with outcomes independent of pulmonary function.

Identifiants

pubmed: 35875881
doi: 10.1111/resp.14333
pmc: PMC9796832
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1045-1053

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.

Références

Chest. 2019 May;155(5):972-981
pubmed: 30742809
Eur Respir J. 2017 Feb 23;49(2):
pubmed: 28232409
Eur Respir J. 2018 Sep 17;52(3):
pubmed: 30139770
Radiology. 2003 Aug;228(2):407-14
pubmed: 12802000
Radiology. 2017 Oct;285(1):270-278
pubmed: 28493789
Lancet Respir Med. 2020 Nov;8(11):1144-1153
pubmed: 32109428
Respirology. 2019 Apr;24(4):361-368
pubmed: 30328644
Thorax. 2019 Dec;74(12):1131-1139
pubmed: 31558622
BMC Pulm Med. 2018 Jan 25;18(1):19
pubmed: 29370786
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Lancet Respir Med. 2018 Nov;6(11):837-845
pubmed: 30232049
Thorax. 2020 Jan;75(1):78-80
pubmed: 31611341
Am J Respir Crit Care Med. 2019 Jan 1;199(1):12-21
pubmed: 29986154
Respirology. 2014 Oct;19(7):1088-91
pubmed: 25123691
Radiology. 2008 Mar;246(3):935-40
pubmed: 18235106
Eur Respir J. 2017 Jan 25;49(1):
pubmed: 27811068
Am J Respir Crit Care Med. 2017 Apr 1;195(7):921-929
pubmed: 27767347
Respirology. 2022 Dec;27(12):1045-1053
pubmed: 35875881
J Thorac Imaging. 2013 Sep;28(5):298-307
pubmed: 23966094
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Acad Radiol. 2015 Jan;22(1):70-80
pubmed: 25262954
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307

Auteurs

Stephen M Humphries (SM)

Department of Radiology, National Jewish Health, Denver, Colorado, USA.

John A Mackintosh (JA)

Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.

Helen E Jo (HE)

NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Simon L F Walsh (SLF)

Department of Radiology, King's College Hospital Foundation Trust, London, UK.

Mario Silva (M)

Section of "Scienze Radiologiche", Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy.
Department of Radiology, University of Massachusetts Medical School, UMass Memorial Health Care, Worcester, Massachusetts, USA.

Lucio Calandriello (L)

Dipartimento di Diagnostica per immagini, Radioterapia, Oncologia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Sally Chapman (S)

Respiratory Consultants, Adelaide, South Australia, Australia.

Samantha Ellis (S)

Department of Radiology, Alfred Health, Melbourne, Victoria, Australia.

Ian Glaspole (I)

NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
Department of Allergy and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia.

Nicole Goh (N)

Respiratory and Sleep Medicine, Austin Hospital, Melbourne, Victoria, Australia.

Christopher Grainge (C)

Department of Respiratory Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.

Peter M A Hopkins (PMA)

Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

Gregory J Keir (GJ)

Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Yuben Moodley (Y)

School of Medicine & Pharmacology, University of Western Australia, Perth, Western Australia, Australia.

Paul N Reynolds (PN)

Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

E Haydn Walters (EH)

Department of Medicine, University of Tasmania, Hobart, Tasmania, Australia.

David Baraghoshi (D)

Division of Biostatistics, National Jewish Health, Denver, Colorado, USA.

Athol U Wells (AU)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.
National Heart and Lung Institute, Imperial College London, London, UK.

David A Lynch (DA)

Department of Radiology, National Jewish Health, Denver, Colorado, USA.

Tamera J Corte (TJ)

NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH